# US 2025/0375392 A1 · Branched Tail Lipids and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375392 A1
- Document ID: US20250375392A1
- Status: Published application
- Kind: A1
- Application number: 19/232,612
- Filed: 2025-06-09
- Published: 2025-12-11
- Earliest claimed: 2024-06-07
- Applicants: Carnegie Mellon University
- Inventors: Kathryn Whitehead; Mariah Lynn Arral
- Web page: https://patentgrep.com/patent/US20250375392A1

## CPC

- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Ionizable lipids having branched tails, nanoparticles containing the ionizable lipids, compositions containing the nanoparticles, and methods for using the ionizable lipids, nanoparticles, and compositions to deliver agents (e.g., RNAs) to cells, tissues, and/or organs are provided herein.

## Claims

### Claim 1

A lipid-containing particle comprising:
a lipidoid;
cholesterol or a derivative thereof;
a helper lipid; and
a polyethylene glycol (PEG)-based compound,
wherein said lipidoid comprises an amine-containing head and one or more acrylate tails, wherein each of said one or more acrylate tails comprises an alkyl chain of 10 or 11 carbon atoms, and wherein said alkyl chain of each of said one or more acrylate tails comprises a one, two, three, four, or five carbon atom branch.

### Claim 2 (depends on 1)

The lipid-containing particle of claim 1, wherein said lipidoid has two, three, or four acrylate tails.

### Claim 3 (depends on 1)

The lipid-containing particle of claim 1, wherein said lipid-containing particle is a lipid nanoparticle (LNP).

### Claim 4 (depends on 1)

The lipid-containing particle of claim 1, wherein said helper lipid is a neutral lipid or a zwitterionic lipid.

### Claim 5 (depends on 1)

The lipid-containing particle of claim 1, wherein said lipidoid comprises an N1-(3-aminopropyl)-N1-methylpropane-1,3-diamine head.

### Claim 6 (depends on 1)

The lipid-containing particle of claim 1, wherein said lipidoid comprises:
a decan-2-yl acrylate tail,
a decan-3-yl acrylate tail,
a decan-4-yl acrylate tail,
a decan-5-yl acrylate tail,
a 2-methylnonyl acrylate tail,
a 2-ethyloctyl acrylate tail,
a 2-propylheptyl acrylate tail,
a 2-butylhexyl acrylate tail,
a 3-methylnonyl acrylate tail,
a 3-ethyloctyl acrylate tail,
a 3-propylheptyl acrylate tail,
a 4-methylnonyl acrylate tail,
a 4-ethyloctyl acrylate tail,
a 4-propylheptyl acrylate tail,
a 5-methynonyl acrylate tail,
a 6-methylnonyl acrylate tail,
a 6-ethyloctyl acrylate tail,
an undecan-3-yl acrylate tail,
an undecan-4-yl acrylate tail,
an undecan-5-yl acrylate tail,
an undecan-6-yl acrylate tail,
a 7-ethylnonyl acrylate tail,
an 8-methyldecyl acrylate tail, or
a 9-methyldecyl acrylate tail.

### Claim 7 (depends on 1)

The lipid-containing particle of claim 1, wherein the cholesterol or a derivative thereof is cholesterol.

### Claim 8 (depends on 1)

The lipid-containing particle of claim 1, wherein the PEG-based compound is a PEG-lipid, and wherein the PEG has a molecular weight of about 300 g/mol to about 5000 g/mol.

### Claim 9 (depends on 1)

The lipid-containing particle of claim 1, wherein one or more of the following is true:
at pH 5.5, said lipid-containing particle has a net positive charge; said lipid-containing particle has a diameter of about 60 nM to about 160 nM;
said lipid containing particle has a zeta potential at pH 7.4 of about −11 mV to about-2 mV; and
said lipid-containing particle has a pKa of about 5.3 to about 7.5.

### Claim 10 (depends on 1)

A composition comprising the lipid-containing particle of claim 1, wherein said lipid-containing particle further comprises a therapeutic agent.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the therapeutic agent comprises RNA.

### Claim 12 (depends on 11)

The composition of claim 11, wherein said RNA comprises messenger RNA (mRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), antisense RNA, guide RNA, long non-coding RNA, transfer RNA, ribosomal RNA, double-stranded RNA (dsRNA), RNA aptamer, or any combination thereof.

### Claim 13 (depends on 10)

The composition of claim 10, wherein said lipidoid comprises an N1-(3-aminopropyl)-N1-methylpropane-1,3-diamine head and a decan-2-yl acrylate tail, a decan-3-yl acrylate tail, a decan-4-yl acrylate tail, a decan-5-yl acrylate tail, a 2-methylnonyl acrylate tail, a 2-ethyloctyl acrylate tail, a 2-propylheptyl acrylate tail, a 2-butylhexyl acrylate tail, a 3-methylnonyl acrylate tail, a 3-ethyloctyl acrylate tail, a 3-propylheptyl acrylate tail, a 4-methylnonyl acrylate tail, a 4-ethyloctyl acrylate tail, a 4-propylheptyl acrylate tail, a 5-methynonyl acrylate tail, a 6-methylnonyl acrylate tail, a 6-ethyloctyl acrylate tail, an undecan-3-yl acrylate tail, an undecan-4-yl acrylate tail, an undecan-5-yl acrylate tail, an undecan-6-yl acrylate tail, a 7-ethylnonyl acrylate tail, an 8-methyldecyl acrylate tail, or a 9-methyldecyl acrylate tail.

### Claim 14 (depends on 1)

A method for delivering a therapeutic agent to a mammal, wherein the method comprises administering to the mammal a composition comprising the lipid-containing particle of claim 1, wherein said lipid-containing particle further comprises said therapeutic agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein said therapeutic agent comprises RNA.

### Claim 16 (depends on 15)

The method of claim 15, wherein said RNA comprises mRNA, siRNA, shRNA, miRNA, antisense RNA, guide RNA, long non-coding RNA, transfer RNA, ribosomal RNA, dsRNA, RNA aptamer, or any combination thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein said lipidoid comprises:
(a) an N1-(3-aminopropyl)-N1-methylpropane-1,3-diamine head; and
(b) a decan-2-yl acrylate tail, a decan-3-yl acrylate tail, a decan-4-yl acrylate tail, a decan-5-yl acrylate tail, a 2-methylnonyl acrylate tail, a 2-ethyloctyl acrylate tail, a 2-propylheptyl acrylate tail, a 2-butylhexyl acrylate tail, a 3-methylnonyl acrylate tail, a 3-ethyloctyl acrylate tail, a 3-propylheptyl acrylate tail, a 4-methylnonyl acrylate tail, a 4-ethyloctyl acrylate tail, a 4-propylheptyl acrylate tail, a 5-methynonyl acrylate tail, a 6-methylnonyl acrylate tail, a 6-ethyloctyl acrylate tail, an undecan-3-yl acrylate tail, an undecan-4-yl acrylate tail, an undecan-5-yl acrylate tail, an undecan-6-yl acrylate tail, a 7-ethylnonyl acrylate tail, an 8-methyldecyl acrylate tail, or a 9-methyldecyl acrylate tail.

### Claim 18

A lipid-containing particle comprising:
a lipidoid;
cholesterol or a derivative thereof;
a helper lipid; and
a polyethylene glycol (PEG)-based compound,
wherein said lipidoid comprises an amine-containing head and one or more acrylate tails, wherein said amine-containing head is N1-(3-aminopropyl)-N1-methylpropane-1,3-diamine, and wherein said one or more acrylate tails comprise one or more of a decan-3-yl acrylate tail, a decan-5-yl acrylate tail, a 2-methylnonyl acrylate tail, a 2-ethyloctyl acrylate tail, a 2-propylheptyl acrylate tail, a 3-ethyloctyl acrylate tail, a 4-ethyloctyl acrylate tail, a 4-propylheptyl acrylate tail, a 5-methynonyl acrylate tail, a 6-ethyloctyl acrylate tail, an undecan-3-yl acrylate tail, an undecan-4-yl acrylate tail, an undecan-5-yl acrylate tail, an undecan-6-yl acrylate tail, a 7-ethylnonyl acrylate tail, an 8-methyldecyl acrylate tail, and a 9-methyldecyl acrylate tail.

### Claim 19 (depends on 18)

A composition comprising the lipid-containing particle of claim 18, wherein said lipid-containing particle further comprises a therapeutic agent.

### Claim 20 (depends on 18)

A method for delivering a therapeutic agent to a mammal, wherein the method comprises administering to the mammal a composition comprising the lipid-containing particle of claim 18, wherein said lipid-containing particle further comprises said therapeutic agent.
